Last reviewed · How we verify
CD11301 0.06%
CD11301 is a topical retinoid that modulates the retinoic acid pathway to treat acne.
CD11301 is a topical retinoid that modulates the retinoic acid pathway to treat acne. Used for Acne vulgaris.
At a glance
| Generic name | CD11301 0.06% |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | retinoid |
| Target | retinoic acid receptors |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
CD11301 works by binding to retinoic acid receptors, which are involved in the regulation of cell growth and differentiation. This leads to a reduction in the formation of comedones and an improvement in the overall appearance of the skin.
Approved indications
- Acne vulgaris
Common side effects
- Skin irritation
Key clinical trials
- A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) (PHASE2)
- Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD11301 0.06% CI brief — competitive landscape report
- CD11301 0.06% updates RSS · CI watch RSS
- Galderma R&D portfolio CI